AbbVie has secured FDA acceptance of a supplemental Biologics License Application (sBLA) for BOTOX Cosmetic targeting masseter muscle prominence—the lower-jaw aesthetic indication that has driven off-label demand for years. The filing signals formal regulatory review is underway.
Regulatory
AbbVie Wins FDA Review for BOTOX Jawline Indication
Supplemental BLA for masseter prominence moves forward, opening a new revenue stream for practices.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Masseter treatment has driven off-label demand for years; FDA approval removes prescriber liability and opens marketing pathways.
This is material for practice economics. Masseter treatment has been a high-volume, high-margin procedure in many medspas and cosmetic dermatology practices, typically requiring 20–50 units per side at premium pricing. FDA approval legitimizes the indication, removes prescriber liability, and opens reimbursement and marketing pathways currently unavailable for off-label use. Expect AbbVie to market aggressively once approved; practices should prepare for patient education and protocol refinement. The indication also raises the stakes for competing toxins seeking similar clearances.
Source: original report ↗
Frequently asked questions
What is the BOTOX masseter indication and how does it differ from current approved uses?
The masseter indication targets the lower-jaw muscle to reduce prominence and create a more refined jawline—an aesthetic outcome that practitioners have been delivering off-label for years. FDA approval removes prescriber liability and enables direct marketing and potential reimbursement pathways that are unavailable for off-label applications.
How many BOTOX units are typically needed for masseter treatment?
Masseter treatment typically requires 20–50 units per side, making it a high-volume procedure that commands premium pricing in most medspas and cosmetic practices. The exact dose depends on muscle mass and desired results.
When will BOTOX be FDA approved for jawline/masseter treatment?
AbbVie's supplemental BLA has been accepted for formal FDA review, but no approval date has been announced yet. Once approved, expect aggressive marketing from AbbVie and increased patient demand as the indication becomes mainstream.
How will BOTOX masseter FDA approval affect my practice revenue?
Approval legitimizes a procedure many practices already perform off-label, enabling direct marketing, potential insurance reimbursement, and reduced liability. Practices should prepare for higher patient inquiries and refine treatment protocols now to capture this demand.
Will other BOTOX competitors seek FDA approval for masseter treatment?
Yes—AbbVie's regulatory progress raises the stakes for competing toxins like Dysport and Xeomin to pursue similar clearances. Expect a competitive filing wave once BOTOX approval is granted.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.